We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Beam Therapeutics (BEAM - Free Report) reported a loss of $1.09 per share for the fourth quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of $1.10. The company had recorded earnings of $1.73 per share in the year-ago quarter.
Total revenues, comprising license and collaboration revenues, came in at $30.1 million in the fourth quarter compared with $316.2 million reported in the year-ago period. The top line beat the Zacks Consensus Estimate of $21 million.
In the past year, shares of Beam Therapeutics have plunged 33.8% compared with the industry’s decline of 9.7%.
Image Source: Zacks Investment Research
More on BEAM's Q4 Results
Research and development expenses were $101.4 million in the fourth quarter, down almost 27.6% from the year-ago quarter’s level.
General and administrative expenses totaled $28.7 million, decreasing around 33.7% year over year.
As of Dec 31, 2024, Beam Therapeutics had cash, cash equivalents and marketable securities worth $850.7 million compared with $925.8 million as of Sept. 30, 2024. The company expects its existing cash balance to likely fund its operating expenses into 2027.
BEAM's Full-Year Results
For 2024, Beam Therapeutics generated revenues of $63.5 million, compared with $377.7 million recorded in the year-ago quarter.
For the same period, the company reported an adjusted loss of $4.58 per share, wider than a loss of $1.72 per share reported in the year-ago period.
BEAM's Pipeline Updates
The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease (SCD).
In December 2024, the company announced new safety and efficacy data from the BEACON study evaluating BEAM-101 in SCD patients with severe vaso-occlusive crises.
The data showed that treatment with BEAM-101 led to a robust and durable increase in fetal hemoglobin and a reduction in sickle hemoglobin.
Treatment with BEAM-101 also demonstrated rapid neutrophil and platelet engraftment and normalized or improved markers of hemolysis in the given patient population.
The company plans to present updated data from the BEACON study in mid-2025.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for treating glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively.
Patient dosing in the phase I/II study evaluating BEAM-301 for treating GSD1a is expected to begin shortly.
The company is developing BEAM-302 in a phase I/II dose-escalation study for treating AATD. Initial data from multiple cohorts of the study are expected in the first half of 2025.
Beam Therapeutics Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for argenx’s earnings per share have increased from $9.07 to $10.85 for 2025. In the past year, shares of ARGX have risen 52%.
ARGX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 339.37%.
In the past 60 days, estimates for Pacira BioSciences’ earnings per share have increased from $2.79 to $3.59 for 2025. In the past year, shares of PCRX have decreased 15.8%.
PCRX’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 7.13%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
Beam Therapeutics (BEAM - Free Report) reported a loss of $1.09 per share for the fourth quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of $1.10. The company had recorded earnings of $1.73 per share in the year-ago quarter.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Total revenues, comprising license and collaboration revenues, came in at $30.1 million in the fourth quarter compared with $316.2 million reported in the year-ago period. The top line beat the Zacks Consensus Estimate of $21 million.
In the past year, shares of Beam Therapeutics have plunged 33.8% compared with the industry’s decline of 9.7%.
Image Source: Zacks Investment Research
More on BEAM's Q4 Results
Research and development expenses were $101.4 million in the fourth quarter, down almost 27.6% from the year-ago quarter’s level.
General and administrative expenses totaled $28.7 million, decreasing around 33.7% year over year.
As of Dec 31, 2024, Beam Therapeutics had cash, cash equivalents and marketable securities worth $850.7 million compared with $925.8 million as of Sept. 30, 2024. The company expects its existing cash balance to likely fund its operating expenses into 2027.
BEAM's Full-Year Results
For 2024, Beam Therapeutics generated revenues of $63.5 million, compared with $377.7 million recorded in the year-ago quarter.
For the same period, the company reported an adjusted loss of $4.58 per share, wider than a loss of $1.72 per share reported in the year-ago period.
BEAM's Pipeline Updates
The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease (SCD).
In December 2024, the company announced new safety and efficacy data from the BEACON study evaluating BEAM-101 in SCD patients with severe vaso-occlusive crises.
The data showed that treatment with BEAM-101 led to a robust and durable increase in fetal hemoglobin and a reduction in sickle hemoglobin.
Treatment with BEAM-101 also demonstrated rapid neutrophil and platelet engraftment and normalized or improved markers of hemolysis in the given patient population.
The company plans to present updated data from the BEACON study in mid-2025.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for treating glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively.
Patient dosing in the phase I/II study evaluating BEAM-301 for treating GSD1a is expected to begin shortly.
The company is developing BEAM-302 in a phase I/II dose-escalation study for treating AATD. Initial data from multiple cohorts of the study are expected in the first half of 2025.
Beam Therapeutics Inc. Price, Consensus and EPS Surprise
Beam Therapeutics Inc. price-consensus-eps-surprise-chart | Beam Therapeutics Inc. Quote
BEAM's Zacks Rank & Other Stocks to Consider
Beam Therapeutics currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are argenx SE (ARGX - Free Report) , and Pacira BioSciences, Inc. (PCRX - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for argenx’s earnings per share have increased from $9.07 to $10.85 for 2025. In the past year, shares of ARGX have risen 52%.
ARGX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 339.37%.
In the past 60 days, estimates for Pacira BioSciences’ earnings per share have increased from $2.79 to $3.59 for 2025. In the past year, shares of PCRX have decreased 15.8%.
PCRX’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 7.13%.